A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.

Vectibix (panitumumab) - Amgen

albumin-bound paclitaxel - Generic mfg.

Erbitux (cetuximab) - Eli Lilly

5-fluorouracil - Generic mfg.

S241656 - Servier

gemcitabine - Generic mfg.

https://www.asco.org/abstracts-presentations/255140

Ajay Prakash; Michael Offin; Manish R. Sharma; Alexander I. Spira; Sylvia Lee; Maria Q. Baggstrom; Agathe Lepissier; Vanessa Seif; Zhaowei Hua; Kabir Mody; Jia Luo; Jiaxin Niu

Dec 2, 2025